GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Accumulated other comprehensive income (loss)

Royalty Pharma (STU:RPD) Accumulated other comprehensive income (loss) : €0 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Royalty Pharma Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Royalty Pharma's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was €0 Mil.

Royalty Pharma Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Royalty Pharma's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Accumulated other comprehensive income (loss) Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial 28.27 14.60 - - -

Royalty Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Royalty Pharma Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Royalty Pharma Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (STU:RPD) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
INCY INSM EXEL BMRN MRNA ASND CORT SMMT ROIV RVMD VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
RPRX:USA RPRX:Mexico
Address
110 East 59th Street, New York, NY, USA, 10022
Website
https://www.royaltypharma.com
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.